Across different clinical syndromes of CBD, 12 out of 18 (67%) and 15 out of 18 (83%) had CSF MTBR-tau275/t-tau and MTBR-tau282/t-tau values lower than cutoff, suggesting that these biomarkers identify CBD regardless of clinical syndromes with up to 83% accuracy. This evidence concerns the gene MAPT and red-green color blindness.